BioAge Labs, Inc.

Pharmaceutical Preparations

BIOA Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001709941 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$389.66M
45,896,909 shares Covers every share class this company has on file.
Insiders on file
4
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$78.88M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
20.24%
insider-held value divided by market capitalisation

What BioAge Labs, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$9.00M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$80.61M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
60
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at BioAge Labs, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against BioAge Labs, Inc..
Insider Reported role Shares Value Last action
Officers who also sit on the board 1
Kristen Fortney CEO 976,949 $9.37M S Open-market sale Jan 13, 2026 position reported
Directors 3
Vijay Satyanand Pande Board Member 3,233,170 $31.01M P Open-market purchase Oct 3, 2024 position reported
James Healy Board Member 2,304,901 $22.10M P Open-market purchase Sep 27, 2024 position reported
Patrick G. Enright Board Member 1,710,589 $16.40M P Open-market purchase Sep 27, 2024 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

James Healy bought 588,888 BioAge Labs, Inc. (BIOA) shares for $10,599,984 on Sep 27, 2024

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

James Healy bought 588,888 BioAge Labs, Inc. (BIOA) shares for $10,599,984 on Sep 27, 2024
Date Insider Transaction Shares Price Value Filing
Sep 27, 2024 James Healy P Open-market purchase 588,888 held after: 2,227,124 $18.00 $10,599,984 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 17 rows we hold, 10 are open-market purchases (P) and 1 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for BioAge Labs, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jan 13, 2026 Kristen Fortney S Open-market sale 233,107 $18.12 $4.22M SEC filing ↗
Oct 3, 2024 Vijay Satyanand Pande P Open-market purchase 25,306 $19.90 $503.6K SEC filing ↗
Oct 2, 2024 Vijay Satyanand Pande P Open-market purchase 67,096 $19.73 $1.32M SEC filing ↗
Oct 1, 2024 Vijay Satyanand Pande P Open-market purchase 126,793 $19.73 $2.50M SEC filing ↗
Sep 27, 2024 Vijay Satyanand Pande C Conversion of derivative 655,294 $0.00 $0 SEC filing ↗
Sep 27, 2024 Vijay Satyanand Pande C Conversion of derivative 855,972 $0.00 $0 SEC filing ↗
Sep 27, 2024 Vijay Satyanand Pande C Conversion of derivative 413,100 $0.00 $0 SEC filing ↗
Sep 27, 2024 Vijay Satyanand Pande P Open-market purchase 900,000 $18.00 $16.20M SEC filing ↗
Sep 27, 2024 Vijay Satyanand Pande C Conversion of derivative 189,609 $0.00 $0 SEC filing ↗
Sep 27, 2024 Patrick G. Enright P Open-market purchase 400,000 $18.00 $7.20M SEC filing ↗
Sep 27, 2024 Patrick G. Enright C Conversion of derivative 1,310,589 $0.00 $0 SEC filing ↗
Sep 27, 2024 James Healy P Open-market purchase 11,113 $18.00 $200.0K SEC filing ↗
Sep 27, 2024 James Healy P Open-market purchase 21,814 $18.00 $392.7K SEC filing ↗
Sep 27, 2024 James Healy P Open-market purchase 18,353 $18.00 $330.4K SEC filing ↗
Sep 27, 2024 James Healy P Open-market purchase 26,497 $18.00 $476.9K SEC filing ↗
Sep 27, 2024 James Healy P Open-market purchase 588,888 $18.00 $10.60M SEC filing ↗
Sep 27, 2024 James Healy C Conversion of derivative 1,638,236 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 3 filers hold a position

Who owns BioAge Labs, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 3 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in BioAge Labs, Inc.

Funds, trusts and companies that disclose an ownership position in BioAge Labs, Inc..
Owner Reported role Shares Filed
Cormorant Asset Management, LP Other,TenPercentOwner 1,629,529 joint
Cormorant Private Healthcare Fund IV LP Other,TenPercentOwner 1,629,529 joint
Cormorant Private Healthcare Fund V LP Other,TenPercentOwner 1,629,529 joint

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from BioAge Labs, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from BioAge Labs, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.